The FDA has approved Seattle Genetics' breast cancer drug Tukysa (tucatinib) four months early, including in certain patients whose disease has spread to the brain. Tukysa has been approved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback